UK guidelines on 18F-fluciclovine PET/CT in prostate cancer imaging.

Published on May 27, 2019in Nuclear Medicine Communications1.334
· DOI :10.1097/MNM.0000000000001030
Asim Afaq14
Estimated H-index: 14
,
Fergus V. Gleeson57
Estimated H-index: 57
+ 11 AuthorsJamshed Bomanji12
Estimated H-index: 12
(UCLH: University College London Hospitals NHS Foundation Trust)
Sources
Abstract
The purpose of these guidelines is to assist specialists in Nuclear Medicine and Radionuclide Radiology in recommending, performing, interpreting and reporting 18F-fluciclovine PET/computed tomography. It should be recognised that adherence to the guidance in this document will not assure an accurat
📖 Papers frequently viewed together
14 Citations
9 Citations
References0
Newest
#1Gerald L. Andriole (WashU: Washington University in St. Louis)H-Index: 97
#2Lale Kostakoglu (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 55
Last. Barry A. Siegel (WashU: Washington University in St. Louis)H-Index: 101
view all 8 authors...
Purpose:The prospective, multicenter LOCATE (18F Fluciclovine [FACBC] PET/CT in Patients with Rising PSA after Initial Prostate Cancer Treatment) trial assessed the impact of positron emission tomography/computerized tomography with 18F-fluciclovine on treatment plans in patients with biochemical recurrence of prostate cancer after primary therapy with curative intent.Materials and Methods:Men who had undergone curative intent treatment of histologically confirmed prostate cancer but who were su...
43 CitationsSource
#1Bital Savir-Baruch (LUC: Loyola University Chicago)H-Index: 12
#2Kevin P. Banks (LUC: Loyola University Chicago)H-Index: 1
Last. David M Schuster (LUC: Loyola University Chicago)H-Index: 1
view all 10 authors...
AbstractThe American College of Radiology (ACR) and American College of Nuclear Medicine (ACNM) collaborated to develop a clinical practice document for the performance of fluciclovine positron-emission tomography (PET) / computed tomography (CT) in the evaluation of patients with suspected prostate
15 CitationsSource
#1Albert ChauH-Index: 1
#2Peter GardinerH-Index: 2
Last. Hossein JadvarH-Index: 38
view all 4 authors...
Purpose18F-fluciclovine is a synthetic amino acid radiotracer that has recently been approved in Europe and the United States for PET imaging in men with biochemical recurrence (BCR) of prostate cancer after prior definitive treatment. Accurate identification of the sites of disease in patients pres
2 CitationsSource
#1Oladunni Akin-Akintayo (Emory University)H-Index: 5
#2Funmilayo Tade (Emory University)H-Index: 7
Last. David M. Schuster (Emory University)H-Index: 33
view all 16 authors...
Abstract Purpose To investigate the disease detection rate, diagnostic performance and interobserver agreement of fluciclovine ( 18 F) PET-CT and multiparametric magnetic resonance imaging (mpMR) in recurrent prostate cancer. Methods Twenty-four patients with biochemical failure after non-prostatectomy definitive therapy, 16/24 of whom had undergone brachytherapy, underwent fluciclovine PET-CT and mpMR with interpretation by expert readers blinded to patient history, PSA and other imaging result...
14 CitationsSource
#1Madeline Cancian (Brown University)H-Index: 4
#2Jorge Pereira (Brown University)H-Index: 4
Last. Joseph Renzulli (Brown University)H-Index: 15
view all 3 authors...
Abstract Background: Multiple new systemic agents have been targeted to metastatic prostate cancer, with decreased progression of disease but no cure. Surgical management of metastatic disease has been gaining interest, primarily in the setting of high-risk prostatectomies. However, metastasis-directed surgical intervention has been employed in rare scenarios, especially in oligometastatic disease. We report here on a salvage robot-assisted pelvic lymph node dissection for a solitary metastatic ...
2 CitationsSource
When biochemical recurrence (BCR) of prostate cancer is suspected, early and accurate localization of metastases facilitates treatment when tumors are small and most amenable to localized therapy, and may guide clinicians in making management plans regarding salvage therapy. Here, we present results of a preplanned analysis of the FALCON trial (NCT02578940), which assessed the impact of PET/CT imaging with 18F-fluciclovine on clinical management choices for men with BCR of prostate cancer.
Source
#2Anne I.J. ArensH-Index: 8
Last. Lioe-Fee de Geus-Oei (LUMC: Leiden University Medical Center)H-Index: 29
view all 8 authors...
In recent years, different metal artifact reduction methods have been developed for CT. These methods have only recently been introduced for PET/CT even though they could be beneficial for interpretation, segmentation, and quantification of the PET/CT images. In this study, phantom and patient scans were analyzed visually and quantitatively to measure the effect on PET images of iterative metal artifact reduction (iMAR) of CT data. Methods: The phantom consisted of 2 types of hip prostheses in a...
15 CitationsSource
#1Matthew P. MillerH-Index: 6
#2Lale Kostakoglu (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 55
Last. Penelope WardH-Index: 25
view all 9 authors...
: 18F-Fluciclovine is a novel PET/CT tracer. This blinded image evaluation (BIE) sought to demonstrate that, after limited training, readers naive to 18F-fluciclovine could interpret 18F-fluciclovine images from subjects with biochemically recurrent prostate cancer with acceptable diagnostic performance and reproducibility. The primary objectives were to establish individual readers' diagnostic performance and the overall interpretation (2/3 reader concordance) compared with standard-of-truth da...
22 CitationsSource
#1Tore Bach-Gansmo (Oslo University Hospital)H-Index: 9
#2Cristina NanniH-Index: 54
Last. Frode Willoch (University of Oslo)H-Index: 30
view all 16 authors...
Purpose: Sensitive detection of cancer foci in men experiencing biochemical recurrence following initial treatment of prostate cancer is of great clinical significance with a possible impact on subsequent treatment choice. We describe a multisite experience of the efficacy and safety of the positron emission tomography/computerized tomography agent fluciclovine (18F) after biochemical recurrence.Materials and Methods: A total of 596 patients underwent fluciclovine (18F) positron emission tomogra...
86 CitationsSource
Purpose To compare the accuracy of 18F-FACBC and 11C-choline PET/CT in patients radically treated for prostate cancer presenting with biochemical relapse.
129 CitationsSource
Cited By2
Newest
#1Ali Baiomy (University of Texas MD Anderson Cancer Center)H-Index: 2
#2Lucia MartiniovaH-Index: 1
Last. Gregory RavizziniH-Index: 10
view all 5 authors...
ABSTRACT A 66-year-old man with prostate adenocarcinoma status post radical retropubic prostatectomy and bilateral pelvic lymph node dissection, followed by salvage external beam radiation therapy to the prostate bed 1 year after surgery. Over the course of 17 years, the patient underwent multiple lines of systemic treatment for recurrent disease. He was referred for restaging 18F-fluciclovine PET/CT due to rising serum prostate-specific antigen levels. Contrast-enhanced 18F-fluciclovine PET/CT ...
Source
#1Qianrui Li (Sichuan University)H-Index: 10
#2Wenxiu Hou (Sichuan University)H-Index: 1
Last. Xin Sun (Sichuan University)H-Index: 68
view all 9 authors...
To examine to what degree guidelines for PET and PET/CT used systematic review evidence. The latest version of guidelines for PET, PET/CT or PET/MRI published in English in PubMed until December 2019 was analysed in two categories: (1) for indications, if mainly discussing the appropriate use of PET in diverse conditions; (2) for procedures, if providing step-by-step instructions for imaging. We surveyed the general characteristics and the use of systematic review evidence for developing recomme...
Source
#1Ajalaya Teyateeti (University of Texas MD Anderson Cancer Center)H-Index: 1
#2Bilal Khan (University of Texas MD Anderson Cancer Center)H-Index: 1
Last. Yang Lu (University of Texas MD Anderson Cancer Center)H-Index: 6
view all 9 authors...
PURPOSE The aim of the study was to assess the diagnostic performance of fluciclovine positron emission tomography (PET)/computerized tomography (CT) in post-radical prostatectomy prostate cancer patients with rising prostate-specific antigen (PSA) ≤0.5 ng/mL, and identify the associated predictive factors of positive studies. PATIENTS AND METHODS From 30 June 2017 to 9 August 2019, patients with post-radical prostatectomy prostate cancer who underwent F-18 fluciclovine PET/CT and had PSA level ...
2 CitationsSource